Skip to main content
PMC home page
Transactions of the American Ophthalmological Society logoLink to Transactions of the American Ophthalmological Society
. 1999;97:115–128.

Ocular safety of Viagra, (sildenafil citrate).

A M Laties 1, F T Fraunfelder 1
PMCID: PMC1298256  PMID: 10703120

Abstract

To date, sildenafil citrate (Viagra) gives every evidence of being a safe drug for the eye despite a series of expressed concerns. A review of how its ocular safety profile has been identified offers insights into the strengths and weaknesses of present systems and resources for judging the ocular safety of Viagra or, for that matter, of any new drug. Such insights include: The great value of careful, informed assessment of preclinical information gleaned from laboratory experiments. By and large, such assessments point the way toward appropriate clinical evaluation. For Viagra, early in its development it was noted that besides exerting a major inhibitory effect on the intended target, the vascular-associated enzyme phosphodiesterase 5 (PDE5), the drug also exerts a lesser but definite inhibitory effect on the closely related PDE6, located in the retina. For this reason, preclinical evaluation of the drug included electroretinography plus postmortem histology. In addition, an extended eye examination was incorporated into clinical protocols. The often chaotic but invaluable information stream that becomes available once marketing approval has been gained and large populations begin to use a drug. False alarms, misattribution, and erroneous information are the order of the day. Nevertheless, as information accumulates, patterns of response clarify and the true nature of special susceptibility for subpopulations, if any, becomes apparent. A role for the astute clinician remains: Subtle changes or unusual risks for subpopulations can be missed entirely for long periods of time. A manifest need for improvement in evaluation of postmarketing side-effects. This need has led to the establishment of a new discipline: pharmacoepidemiology. In ophthalmology, the National Registry of Drug Induced Ocular Side-Effects maintains a constant and invaluable surveillance. Examples are supplied to illustrate each of these major points: Our presentation will include data gleaned from clinical trials plus postmarketing information on the incidence, duration, and type of color vision defects observed at different doses of Viagra.

Full text

PDF
118

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Alvarez-Requejo A., Carvajal A., Bégaud B., Moride Y., Vega T., Arias L. H. Under-reporting of adverse drug reactions. Estimate based on a spontaneous reporting scheme and a sentinel system. Eur J Clin Pharmacol. 1998 Aug;54(6):483–488. doi: 10.1007/s002280050498. [DOI] [PubMed] [Google Scholar]
  2. Ballard S. A., Gingell C. J., Tang K., Turner L. A., Price M. E., Naylor A. M. Effects of sildenafil on the relaxation of human corpus cavernosum tissue in vitro and on the activities of cyclic nucleotide phosphodiesterase isozymes. J Urol. 1998 Jun;159(6):2164–2171. doi: 10.1016/S0022-5347(01)63299-3. [DOI] [PubMed] [Google Scholar]
  3. Beavo J. A. Cyclic nucleotide phosphodiesterases: functional implications of multiple isoforms. Physiol Rev. 1995 Oct;75(4):725–748. doi: 10.1152/physrev.1995.75.4.725. [DOI] [PubMed] [Google Scholar]
  4. Boolell M., Allen M. J., Ballard S. A., Gepi-Attee S., Muirhead G. J., Naylor A. M., Osterloh I. H., Gingell C. Sildenafil: an orally active type 5 cyclic GMP-specific phosphodiesterase inhibitor for the treatment of penile erectile dysfunction. Int J Impot Res. 1996 Jun;8(2):47–52. [PubMed] [Google Scholar]
  5. Brewer T., Colditz G. A. Postmarketing surveillance and adverse drug reactions: current perspectives and future needs. JAMA. 1999 Mar 3;281(9):824–829. doi: 10.1001/jama.281.9.824. [DOI] [PubMed] [Google Scholar]
  6. Donahue S. P., Taylor R. J. Pupil-sparing third nerve palsy associated with sildenafil citrate (Viagra). Am J Ophthalmol. 1998 Sep;126(3):476–477. doi: 10.1016/s0002-9394(98)00243-8. [DOI] [PubMed] [Google Scholar]
  7. Estrade M., Grondin P., Cluzel J., Bonhomme B., Doly M. Effect of a cGMP-specific phosphodiesterase inhibitor on retinal function. Eur J Pharmacol. 1998 Jul 10;352(2-3):157–163. doi: 10.1016/s0014-2999(98)00346-x. [DOI] [PubMed] [Google Scholar]
  8. Feenstra J., van Drie-Pierik R. J., Laclé C. F., Stricker B. H. Acute myocardial infarction associated with sildenafil. Lancet. 1998 Sep 19;352(9132):957–958. doi: 10.1016/s0140-6736(98)00015-4. [DOI] [PubMed] [Google Scholar]
  9. Felix R. H., Ive F. A., Dahl M. G. Cutaneous and ocular reactions to practolol. Br Med J. 1974 Nov 9;4(5940):321–324. doi: 10.1136/bmj.4.5940.321. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Flach A. J. Glaucoma and impotence. JAMA. 1990 Dec 26;264(24):3146–3146. [PubMed] [Google Scholar]
  11. Goldstein I., Lue T. F., Padma-Nathan H., Rosen R. C., Steers W. D., Wicker P. A. Oral sildenafil in the treatment of erectile dysfunction. Sildenafil Study Group. N Engl J Med. 1998 May 14;338(20):1397–1404. doi: 10.1056/NEJM199805143382001. [DOI] [PubMed] [Google Scholar]
  12. Markovits A. S. Ophthalmodynia hypertonica copulatonis a new syndrome? Can J Ophthalmol. 1974 Oct;9(4):484–485. [PubMed] [Google Scholar]
  13. Morales A., Gingell C., Collins M., Wicker P. A., Osterloh I. H. Clinical safety of oral sildenafil citrate (VIAGRA) in the treatment of erectile dysfunction. Int J Impot Res. 1998 Jun;10(2):69–74. doi: 10.1038/sj.ijir.3900354. [DOI] [PubMed] [Google Scholar]
  14. Moreland R. B., Goldstein I., Traish A. Sildenafil, a novel inhibitor of phosphodiesterase type 5 in human corpus cavernosum smooth muscle cells. Life Sci. 1998;62(20):PL–318. doi: 10.1016/s0024-3205(98)00158-1. [DOI] [PubMed] [Google Scholar]
  15. REIVICH M., HOLLING H. E., ROBERTS B., TOOLE J. F. Reversal of blood flow through the vertebral artery and its effect on cerebral circulation. N Engl J Med. 1961 Nov 2;265:878–885. doi: 10.1056/NEJM196111022651804. [DOI] [PubMed] [Google Scholar]
  16. Vobig M. A., Klotz T., Staak M., Bartz-Schmidt K. U., Engelmann U., Walter P. Retinal side-effects of sildenafil. Lancet. 1999 Jan 30;353(9150):375–375. doi: 10.1016/s0140-6736(98)05473-7. [DOI] [PubMed] [Google Scholar]

Articles from Transactions of the American Ophthalmological Society are provided here courtesy of American Ophthalmological Society

RESOURCES